Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New company launched to tackle canine osteoarthritis
The new company - Vetosine - will develop and commercialise new disease modifying osteoarthritis drugs (DMOAD) for dogs.

Human and animal health companies partner up to develop disease modifying drug.

Swiss animal health group Stonehaven Incubate has partnered with Regenosine – specialists in musculoskeletal regenerative therapies – to launch a new company focused on developing disease modifying osteoarthritis drugs for dogs.

The new company, named Vetosine, will produce adenosine-based treatments. Co-founder of Regenosine Dr Bruce Cronstein was one of the first researchers to highlight the role of adenosine in maintaining healthy joint cartilage.

Charlie Dawson, venture partner at Stonehaven Incubate, commented: “At the moment, veterinarians and pet owners have few therapy options for dogs with osteoarthritis beyond simple nonsteroidal anti-inflammatory drugs (NSAIDs), diet and exercise. Vetosine will provide a proven disease modifying drug that will strengthen clinical outcomes and improve the pet’s quality of life.”

Dr. Siddhesh Angle, co-founder and CEO of Regenosine, said: “We have now developed proprietary formulations for adenosine replacement which have demonstrated disease modifying outcomes in gold standard preclinical models for osteoarthritis.”

“While we endeavour to make this first-in-class therapy a success for human medicine, we are very excited to partner with Stonehaven Incubate to expand its horizon into the animal health space.”

According to Stonehaven Incubate, Vetosine will have an exclusive global license to develop the new technology in animal health, while Regenosine will maintain its focus on developing the same technology for the human health sector.

 

Become a member or log in to add this story to your CPD history

RUMA CA&E extends survey deadline

News Story 1
 RUMA CA&E has extended the deadline for its online survey into vaccine availability.

Vets, SQPs, retailers and wholesalers will now have until Friday, 26 September at 5pm to submit their response.

The survey aims to further understanding into the vaccine supply challenges faced by the sector. It will also consider the short and long term impacts of disruption issues.

Insights are anonymous, and will be shared with industry stakeholders and government bodies.

The survey can be accessed here

Click here for more...
News Shorts
BSAVA publishes Guide to Nutrition in Small Animal Practice

The BSAVA has added a small animal nutrition advice booklet to its series of BSAVA guides.

The BSAVA Guide to Nutrition in Small Animal Practice offers a resource for veterinary professionals to provide appropriate nutrition for animals. As well as maintaining the wellbeing of healthy pets, the guide explores how nutritional requirements change in times of illness and disease.

The guide is divided into five sections, which explore the importance of nutritional assessment; diet types; feeding at different life stages; feeding for specific situations; and feeding for specific diseases. Online resources are also in the BSAVA Library including client handouts and videos.

It is designed to be suitable for referencing, in-depth case planning and team training sessions.

The BSAVA Guide to Nutrition in Small Animal Practice can be purchased online from the BSAVA store.